AngioDynamics First Quarter 2025 Earnings: EPS Misses Expectations

AngioDynamics (NASDAQ:ANGO) First Quarter 2025 Results

Key Financial Results

• Revenue: US$67.5m (down 14% from 1Q 2024).
• Net loss: US$12.8m (down by 128% from US$45.9m profit in 1Q 2024).
• US$0.32 loss per share (down from US$1.15 profit in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

AngioDynamics EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 32%.

Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 15% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for AngioDynamics that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.